We describe a case of acute HIV infection in the third trimester of pregnancy associated with an extremely high viral load and the use of raltegravir to prevent HIV mother-to-child transmission.
BirkheadGS, PulverWP, WarrenBL, HackelS, RodríguezD, SmithL. Acquiring human immunodeficiency virus during pregnancy and mother-to-child transmission in New York: 2002-2006.Obstet Gynecol2010; 115: 1247
2.
MoodleyD, EsterhuizenTM, PatherT, ChettyV, NgalekaL. High HIV incidence during pregnancy: compelling reason for repeat HIV testing.AIDS2009; 23: 1255
3.
GrayRH, LiX, KigoziG. Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study.Lancet2005; 366: 1182–8
4.
SheffieldJS, WendelGD, McLntireDD, NorgardMV. The effect of progesterone levels and pregnancy on HIV-1 coreceptor expression.Reprod Sa2009; 16: 20
5.
BoutwellCL, RollandMM, HerbeckJT, MullinsJI, AllenTM. Viral evolution and escape during acute HIV-1 infection.J Infect Dis2010; 202: S309
6.
GarciaPM, KalishLA, PittJ. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmissionN Eng J Med1999; 341: 394
7.
PattersonKB, LeonePA, FiscusSA. Frequent detection of acute HIV infection in pregnant women.AIDS2007; 21: 2303
8.
LennoxJL, DeJesusE, LazzarinA. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.Lancet2009; 374: 796–806
9.
MarkowitzM, NguyenBY, GotuzzoE. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.JAIDS J Acquir Immune Defic Syndr2007; 46: 125
10.
BrainardDM, WenningLA, StoneJA, WagnerJA, IwamotoM. Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor.J Clin Pharmacol2011; S1: 1376–1402
11.
PinnettiC, BaroncelliS, VillaniP. Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy.J Antimicrob Chemother2010; 65: 2050
12.
McKeownDA, RosenvingeM, DonaghyS. High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women.AIDS2010; 24: 2416
13.
TaylorN, TouzeauV, GeitM. Raltegravir in pregnancy: a case series presentation.Int J STD AIDS2011; 22: 358–60
14.
ReadPJ, MandaliaS, KhanP. When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery?AIDS2012; 26: 1095–103
15.
CooperER, CharuratM, MofensonL. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission.JAIDS J Acquir Immune Defic Syndr2002; 29: 484
